Celgene Corp (CELG) 120.43 $CELG Midday Glance:
Post# of 64200
Posted On: 03/16/2015 1:37:15 PM
Celgene Corp (CELG) 120.43 $CELG
Midday Glance: Biotechnology companies
AP - 17 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 100.97 (+1.36), AMGN: 162.13 (+7.87), CELG: 120.43 (+2.70)
Early Glance: Biotechnology companies
AP - Mon Mar 16, 9:34AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 100.97 (+1.36), AMGN: 162.13 (+7.87), CELG: 120.43 (+2.70)
3 Biotech Stocks Wall Street Loves
Keith Speights, The Motley Fool - Motley Fool - Mon Mar 16, 7:01AM CDT
Source: Wikimedia Commons . How can you know when Wall Street really loves a stock? One key sign is how many of the analysts covering the stock maintain buy ratings. Another tell-tale indicator is the price targets these analysts give for the...
GILD: 100.97 (+1.36), ALXN: 179.05 (+2.16), CELG: 120.43 (+2.70)
Should Gilead Sciences Inc.’s Slowing Growth Concern Investors?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 15, 7:57AM CDT
The failure of the market to buy into Gilead Sciences ' amazing growth story is a flat-out mystery in the eyes of many investors. Despite growing product sales by an astounding 127% and non-GAAP earnings per share by 297% last year, the stock has...
BIIB: 420.50 (+7.15), ESRX: 83.52 (+2.15), GILD: 100.97 (+1.36), AMGN: 162.13 (+7.87), ABBV: 58.88 (+0.88), CELG: 120.43 (+2.70)
The Average American Spends This Much On Healthcare Every Year -- Do You?
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 15, 7:03AM CDT
Source: Flickr user 401kcalculator.org According to the annual healthcare spending report that is put together by the Centers for Medicare and Medicaid Services, Americans spend $3 trillion (yes, with a T) on healthcare every year. That spending is...
HCA: 72.97 (+1.17), ANTM: 153.28 (+3.27), UNH: 117.65 (+2.40), CYH: 50.36 (+0.13), CELG: 120.43 (+2.70)
Celgene, Kinder Morgan and Actavis Set to Join the S&P 100; Several Constituent Changes Announced for S&P 500, S&P MidCap 400 and S&P SmallCap 600
PR Newswire - Fri Mar 13, 4:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 100, S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
KMI: 40.48 (+0.56), BDX: 143.88 (+2.03), AVP: 7.30 (-0.42), ACT: 304.09 (+5.14), TLMR: 15.38 (+0.56), NBR: 11.62 (-0.34), FCX: 17.65 (-0.49), SLG: 128.78 (+1.36), MHFI: 105.83 (+1.54), BWLD: 189.42 (+4.85), CELG: 120.43 (+2.70), NOV: 48.16 (-0.91), EQIX: 237.10 (+6.61), CFN: 60.13 (+0.16), APA: 59.12 (-0.24), HBI: 33.65 (+1.04), DNR: 7.12 (-0.19), HSIC: 139.82 (+3.45), CELGZ: 3.02 (-0.03)
Final Glance: Biotechnology companies
AP - Thu Mar 12, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 100.97 (+1.36), AMGN: 162.13 (+7.87), CELG: 120.43 (+2.70)
How to Trade 5 Big Stocks for Big Gains: Must-See Charts
at The Street - Thu Mar 12, 11:06AM CDT
Here's how to trade some of the biggest stocks on Wall Street.
F: 16.40 (+0.20), IBM: 155.95 (+1.67), UNH: 117.65 (+2.40), WFC: 55.61 (+0.27), CELG: 120.43 (+2.70)
Will Biogen Drug Score Big At Alzheimer's Conference?
at Investor's Business Daily - Wed Mar 11, 8:52AM CDT
A new research note from RBC Capital Markets offers a bullish take on Biogen Idec's (BIIB) experimental drug for Alzheimer's disease, predicting it will make a big splash at the upcoming International Conference on Alzheimer's and Parkinson's...
JNJ: 100.64 (+1.43), BIIB: 420.50 (+7.15), GILD: 100.97 (+1.36), PFE: 34.44 (+0.44), AMGN: 162.13 (+7.87), LLY: 71.10 (+1.21), CELG: 120.43 (+2.70)
Cellectis: Finding Value In A Crowded CAR-T Space
Bay Area Biotech - at Seeking Alpha - Tue Mar 10, 8:51PM CDT
Chimeric Antigen Receptor (CAR)-engineered T-cells are an exciting, emerging new space in cancer therapy. At recent American Society of Hematology (ASH) annual meetings, the CAR presentations were met with the most fanfare, attention,...
BLUE: 122.98 (+3.05), ZIOP: 13.10 (-0.22), PFE: 34.44 (+0.44), XON: 45.69 (-0.80), AMGN: 162.13 (+7.87), GSK: 46.94 (+0.57), IMUC: 0.56 (-0.01), CELG: 120.43 (+2.70), JNJ: 100.64 (+1.43), BLCM: 24.60 (+1.77), KITE: 63.10 (+0.01), JUNO: 52.62 (+3.13), NVS: 97.98 (+0.94)
3 Stocks to Buy Following Earnings Season
Matthew Frankel, Dan Caplinger, and Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 10, 5:29AM CDT
With earnings season in the books, we've seen a lot of surprises, some good and some bad. We asked three of our analysts for the best stocks to buy now that earnings season is behind us. Here's what they had to say: Dan Caplinger: One of the...
TRIP: 82.70 (+0.18), PG: 83.26 (+1.43), CELG: 120.43 (+2.70)
Biotechnology Boom
Young Money Monsters - at Seeking Alpha - Tue Mar 10, 4:48AM CDT
Editor's note: Originally published on March 6, 2015 by Jacob Urban Biotechnology has been the topic of many investment conversations of late, and as of now there might not be a hotter sector. Despite the rise in biotechnology over the past...
BBP: 31.84 (+0.27), PBE: 57.00 (+0.83), BIIB: 420.50 (+7.15), SBIO: 30.68 (+0.27), BBC: 33.77 (+0.32), GILD: 100.93 (+1.32), FBT: 123.39 (+2.52), XBI: 230.56 (+2.13), BBH: 133.25 (+2.94), AMGN: 162.13 (+7.87), CELG: 120.43 (+2.70)
Oncology Biotech Company Could Be on the Cusp of New PRP Drug for the Treatment and Prevention of Metastatic Cancer
ACCESSWIRE - Mon Mar 09, 9:37AM CDT
WINDSOR, ON / ACCESSWIRE / March 9, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known Biotech stocks, would like to announce some recent breakthroughs in the development of new cancer treatments, and the companies that play in the field.
BLUE: 122.98 (+3.05), BIIB: 420.50 (+7.15), GILD: 100.93 (+1.32), KITE: 63.10 (+0.01), ARIA: 8.67 (+0.19), CELG: 120.43 (+2.70)
Midday Glance: Biotechnology companies
AP - 17 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 100.97 (+1.36), AMGN: 162.13 (+7.87), CELG: 120.43 (+2.70)
Early Glance: Biotechnology companies
AP - Mon Mar 16, 9:34AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 100.97 (+1.36), AMGN: 162.13 (+7.87), CELG: 120.43 (+2.70)
3 Biotech Stocks Wall Street Loves
Keith Speights, The Motley Fool - Motley Fool - Mon Mar 16, 7:01AM CDT
Source: Wikimedia Commons . How can you know when Wall Street really loves a stock? One key sign is how many of the analysts covering the stock maintain buy ratings. Another tell-tale indicator is the price targets these analysts give for the...
GILD: 100.97 (+1.36), ALXN: 179.05 (+2.16), CELG: 120.43 (+2.70)
Should Gilead Sciences Inc.’s Slowing Growth Concern Investors?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 15, 7:57AM CDT
The failure of the market to buy into Gilead Sciences ' amazing growth story is a flat-out mystery in the eyes of many investors. Despite growing product sales by an astounding 127% and non-GAAP earnings per share by 297% last year, the stock has...
BIIB: 420.50 (+7.15), ESRX: 83.52 (+2.15), GILD: 100.97 (+1.36), AMGN: 162.13 (+7.87), ABBV: 58.88 (+0.88), CELG: 120.43 (+2.70)
The Average American Spends This Much On Healthcare Every Year -- Do You?
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 15, 7:03AM CDT
Source: Flickr user 401kcalculator.org According to the annual healthcare spending report that is put together by the Centers for Medicare and Medicaid Services, Americans spend $3 trillion (yes, with a T) on healthcare every year. That spending is...
HCA: 72.97 (+1.17), ANTM: 153.28 (+3.27), UNH: 117.65 (+2.40), CYH: 50.36 (+0.13), CELG: 120.43 (+2.70)
Celgene, Kinder Morgan and Actavis Set to Join the S&P 100; Several Constituent Changes Announced for S&P 500, S&P MidCap 400 and S&P SmallCap 600
PR Newswire - Fri Mar 13, 4:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 100, S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
KMI: 40.48 (+0.56), BDX: 143.88 (+2.03), AVP: 7.30 (-0.42), ACT: 304.09 (+5.14), TLMR: 15.38 (+0.56), NBR: 11.62 (-0.34), FCX: 17.65 (-0.49), SLG: 128.78 (+1.36), MHFI: 105.83 (+1.54), BWLD: 189.42 (+4.85), CELG: 120.43 (+2.70), NOV: 48.16 (-0.91), EQIX: 237.10 (+6.61), CFN: 60.13 (+0.16), APA: 59.12 (-0.24), HBI: 33.65 (+1.04), DNR: 7.12 (-0.19), HSIC: 139.82 (+3.45), CELGZ: 3.02 (-0.03)
Final Glance: Biotechnology companies
AP - Thu Mar 12, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 100.97 (+1.36), AMGN: 162.13 (+7.87), CELG: 120.43 (+2.70)
How to Trade 5 Big Stocks for Big Gains: Must-See Charts
at The Street - Thu Mar 12, 11:06AM CDT
Here's how to trade some of the biggest stocks on Wall Street.
F: 16.40 (+0.20), IBM: 155.95 (+1.67), UNH: 117.65 (+2.40), WFC: 55.61 (+0.27), CELG: 120.43 (+2.70)
Will Biogen Drug Score Big At Alzheimer's Conference?
at Investor's Business Daily - Wed Mar 11, 8:52AM CDT
A new research note from RBC Capital Markets offers a bullish take on Biogen Idec's (BIIB) experimental drug for Alzheimer's disease, predicting it will make a big splash at the upcoming International Conference on Alzheimer's and Parkinson's...
JNJ: 100.64 (+1.43), BIIB: 420.50 (+7.15), GILD: 100.97 (+1.36), PFE: 34.44 (+0.44), AMGN: 162.13 (+7.87), LLY: 71.10 (+1.21), CELG: 120.43 (+2.70)
Cellectis: Finding Value In A Crowded CAR-T Space
Bay Area Biotech - at Seeking Alpha - Tue Mar 10, 8:51PM CDT
Chimeric Antigen Receptor (CAR)-engineered T-cells are an exciting, emerging new space in cancer therapy. At recent American Society of Hematology (ASH) annual meetings, the CAR presentations were met with the most fanfare, attention,...
BLUE: 122.98 (+3.05), ZIOP: 13.10 (-0.22), PFE: 34.44 (+0.44), XON: 45.69 (-0.80), AMGN: 162.13 (+7.87), GSK: 46.94 (+0.57), IMUC: 0.56 (-0.01), CELG: 120.43 (+2.70), JNJ: 100.64 (+1.43), BLCM: 24.60 (+1.77), KITE: 63.10 (+0.01), JUNO: 52.62 (+3.13), NVS: 97.98 (+0.94)
3 Stocks to Buy Following Earnings Season
Matthew Frankel, Dan Caplinger, and Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 10, 5:29AM CDT
With earnings season in the books, we've seen a lot of surprises, some good and some bad. We asked three of our analysts for the best stocks to buy now that earnings season is behind us. Here's what they had to say: Dan Caplinger: One of the...
TRIP: 82.70 (+0.18), PG: 83.26 (+1.43), CELG: 120.43 (+2.70)
Biotechnology Boom
Young Money Monsters - at Seeking Alpha - Tue Mar 10, 4:48AM CDT
Editor's note: Originally published on March 6, 2015 by Jacob Urban Biotechnology has been the topic of many investment conversations of late, and as of now there might not be a hotter sector. Despite the rise in biotechnology over the past...
BBP: 31.84 (+0.27), PBE: 57.00 (+0.83), BIIB: 420.50 (+7.15), SBIO: 30.68 (+0.27), BBC: 33.77 (+0.32), GILD: 100.93 (+1.32), FBT: 123.39 (+2.52), XBI: 230.56 (+2.13), BBH: 133.25 (+2.94), AMGN: 162.13 (+7.87), CELG: 120.43 (+2.70)
Oncology Biotech Company Could Be on the Cusp of New PRP Drug for the Treatment and Prevention of Metastatic Cancer
ACCESSWIRE - Mon Mar 09, 9:37AM CDT
WINDSOR, ON / ACCESSWIRE / March 9, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known Biotech stocks, would like to announce some recent breakthroughs in the development of new cancer treatments, and the companies that play in the field.
BLUE: 122.98 (+3.05), BIIB: 420.50 (+7.15), GILD: 100.93 (+1.32), KITE: 63.10 (+0.01), ARIA: 8.67 (+0.19), CELG: 120.43 (+2.70)
(0)
(0)